MedTrace Logo

Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.

NCT03838744 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2024-12-04

No results posted yet for this study

Summary

Phase II study in patient with advanced Soft Tissue Sarcoma (STS) patients who have already received or are not suitable, for a doxorubicin-based treatment.

Conditions

  • Advanced Soft Tissue Sarcoma

Interventions

DRUG

Standard arm: Trabectedin in monotherapy

Trabectedin in monotherapy

DRUG

Experimental arm: Trabectedin + Olaparib

Trabectedin given in combination to olaparib

Sponsors & Collaborators

  • PharmaMar

    collaborator INDUSTRY

  • AstraZeneca

    collaborator INDUSTRY

  • Italian Sarcoma Group

    lead NETWORK

Principal Investigators

  • Giovanni Giovanni, MD · Fondazione del Piemonte IRCCS di Candiolo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-20
Primary Completion
2024-11-29
Completion
2024-11-29

Countries

  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03838744 on ClinicalTrials.gov